The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and ...

Three decades of data from the Global Burden of Disease Study were analyzed for trends in global, regional, and national ...

Findings from the SUMMIT, Altshock-2, and FAIR-HF2 trials were presented at the American College of Cardiology 2025 Annual ...

A real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes.

FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration ...

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based ...

As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency ...

Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care ...

In a series of interviews, experts highlight lasting health care innovations that emerged during the COVID-19 pandemic, including telemedicine, artificial intelligence (AI), and home-based treatment.

Experts discuss how current coverage policies and prior authorization requirements affect continuous glucose monitoring (CGM) access and adoption rates, and how coverage barriers impact the ability to ...

Experts discuss how bispecifics might be incorporated earlier in the lines of treatment for certain cancers, the steps that can be taken to improve access to bispecific therapies in underserved or ...

Experts discuss innovations and advancements in bispecific antibodies that could transform their use in the next 5 years.